We are a socially responsible specialty biopharmaceutical company developing disruptive cannabinoid based therapeutics.

Intellectual Property

We currently hold an exclusive license with National Institutes of Health (NIH) for the Commercialization of U.S. Patent #6630507, “Cannabinoids as Antioxidants and Neuroprotectants”

Clinical R&D

Conducting clinical research and development at the Pennsylvania Biotechnology Center of Bucks County in Doylestown, PA

Phytochemical Identification

Materials Transfer and Testing with the Baruch S. Blumberg Institute's Natural Product Discovery Library. The library is regarded as one of the best collections of screen ready druggable libraries made from living organisms.

2010

Year the company was founded

85

Number of known isolated phytocannabinoids from the cannabis plant

3

Number of disease targets Kannalife is working on; Hepatic Encephalopathy (HE), Chronic Traumatic Encephalopathy (CTE) and Chemotherapy Induced Peripheral Neuropathy (CIPN)

100k +

Natural products collection of extracts from plants, fungi, and bacteria available for testing